Leerink Partnrs Has Negative Outlook of DSGN Q2 Earnings

Design Therapeutics, Inc. (NASDAQ:DSGN) – Equities researchers at Leerink Partnrs cut their Q2 2025 earnings estimates for Design Therapeutics in a report issued on Wednesday, May 7th. Leerink Partnrs analyst J. Schwartz now forecasts that the company will earn ($0.33) per share for the quarter, down from their previous estimate of ($0.26). The consensus estimate for Design Therapeutics’ current full-year earnings is ($0.91) per share. Leerink Partnrs also issued estimates for Design Therapeutics’ Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.33) EPS, FY2025 earnings at ($1.30) EPS and FY2026 earnings at ($1.49) EPS.

Design Therapeutics (NASDAQ:DSGN) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.03).

Design Therapeutics Stock Performance

Shares of NASDAQ:DSGN opened at $3.57 on Monday. The company has a fifty day moving average of $3.98 and a 200-day moving average of $4.93. The company has a market capitalization of $202.67 million, a PE ratio of -4.20 and a beta of 1.77. Design Therapeutics has a 52-week low of $2.60 and a 52-week high of $7.77.

Institutional Trading of Design Therapeutics

Institutional investors have recently modified their holdings of the business. American Century Companies Inc. grew its stake in shares of Design Therapeutics by 19.9% in the fourth quarter. American Century Companies Inc. now owns 39,115 shares of the company’s stock worth $241,000 after purchasing an additional 6,481 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Design Therapeutics by 186.9% in the third quarter. JPMorgan Chase & Co. now owns 40,687 shares of the company’s stock worth $219,000 after purchasing an additional 26,503 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Design Therapeutics by 2.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 264,675 shares of the company’s stock worth $1,633,000 after purchasing an additional 7,243 shares during the last quarter. Barclays PLC grew its stake in shares of Design Therapeutics by 34.2% in the third quarter. Barclays PLC now owns 96,635 shares of the company’s stock worth $520,000 after purchasing an additional 24,602 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Design Therapeutics by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 761,640 shares of the company’s stock worth $4,700,000 after purchasing an additional 3,090 shares during the last quarter. Institutional investors own 56.64% of the company’s stock.

Design Therapeutics Company Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.